Introduction
Expression of activated Ras, Raf or other oncoproteins in primary cells often provokes cellular senescence, a permanent state of proliferative arrest that is activated by oncogenic stress (Campisi, 2005; Collado et al, 2007) . This cytostatic response, termed oncogene-induced senescence (OIS), functions as an intrinsic tumour suppression mechanism in cells that have sustained critical levels of oncogenic flux (Sarkisian et al, 2007; Prieur and Peeper, 2008) . OIS is implemented primarily through induction of the p19 Arf -p53 tumour suppressor pathway and CDK inhibitors such as p16
Ink4a and p21
CIP1 that activate Rb-dependent checkpoints (Adams, 2009) . Disruption of these and other anti-oncogenic effectors through mutation or epigenetic silencing leads to senescence bypass and renders cells susceptible to transformation by Ras and other oncogenes (Lowe et al, 2004) .
Recent studies have also implicated the transcription factor C/EBPb and pro-inflammatory mediators such as IL-6, chemokines, and their receptors, comprising a 'senescenceassociated secretory phenotype' (SASP), in senescence induction triggered by oncogenes or DNA damage (Sebastian et al, 2005; Acosta et al, 2008; Kuilman et al, 2008; Rodier et al, 2009 ). Genetic experiments demonstrate that C/EBPb is required for Ras-or BRAF-induced senescence of mouse embryonic fibroblasts (MEFs; Sebastian et al, 2005) and human diploid fibroblasts (Acosta et al, 2008; Kuilman et al, 2008) , in part through its ability to activate SASP genes and p15
Ink4b
. Although C/EBPb and SASP genes are important regulators of OIS, they differ from classical tumour suppressors in that they are rarely, if ever, inactivated in cancers and also exert pro-oncogenic effects in many transformed cells (Sebastian and Johnson, 2006; Mantovani et al, 2008) . Currently, it is unclear how such factors can be critical for establishing senescence while promoting cancer in other contexts.
C/EBPb is maintained in a latent, low-activity state by several auto-inhibitory elements that suppress its DNA-binding and transactivation functions (Kowenz-Leutz et al, 1994; Williams et al, 1995; Lee et al, 2010a) . In response to oncogenic Ras or other stimuli, C/EBPb becomes de-repressed by signalling through the RAF-MEK-ERK cascade (Nakajima et al, 1993; Kowenz-Leutz et al, 1994; Lee et al, 2010b) , in part due to phosphorylation on Thr188 (mouse C/EBPb) by ERK1/2 that leads to altered binding of mediator complexes (Mo et al, 2004) . Oncogenic Ras also stimulates C/EBPb's anti-proliferative activity and increases the ratio of C/EBPb homodimers to C/EBPb:C/EBPg heterodimers by a mechanism involving phosphorylation on leucine zipper residue Ser273 by p90
Rsk kinases (Lee et al, 2010b) . These observations, together with the fact that C/EBPg-deficient MEFs display severe proliferative defects, have led to the notion that the hyperactivated, homodimeric form of C/EBPb contributes to Ras-induced cell-cycle arrest and senescence in primary cells, whereas b:g heterodimers are permissive for, or actively promote, mitotic growth (Lee et al, 2010b) . However, this model does not explain how transformed cells, particularly those harbouring Ras or BRAF oncogenes, evade the anti-proliferative effects of activated C/EBPb. In NIH 3T3 cells, endogenous C/EBPb expression is downregulated by Ras V12 , providing one possible mechanism (Sebastian and Johnson, 2009 ). Nevertheless, many transformed cells express relatively high levels of C/EBPb, suggesting that other means exist to constrain its anti-proliferative activity.
Here, we report the unexpected finding that Ras-induced post-translational activation of C/EBPb is inhibited by the 3 0 untranslated region (3 0 UTR) of its mRNA, suppressing the cytostatic and pro-senescence functions of C/EBPb selectively in immortalized and transformed cells. These observations, thus, identify a new function for 3 0 UTRs and suggest a further basis for senescence bypass in cancer cells.
Results

The Cebpb 3
0 UTR blocks the Ras-induced cytostatic functions of C/EBPb Introduction of oncogenic H-Ras V12 in immortalized NIH 3T3 fibroblasts silences C/EBPb expression through a mechanism requiring absence of the tumour suppressor p19
Arf (Sebastian and Johnson, 2009 ). Ectopic C/EBPb expression in Ras V12 -transformed NIH 3T3 (3T3 Ras ) cells suppresses proliferation and transformation and induces a flat, senescent-like morphology, suggesting that downregulation of endogenous C/EBPb is involved in neoplastic transformation of these cells. To explore a possible role for Cebpb 3 0 UTR sequences in C/EBPb downregulation by Ras V12 (e.g., via miRNAmediated silencing), we used retroviral infection to introduce the C/EBPb coding region alone (C/EBPb CR ) or the coding region plus 3 0 UTR (C/EBPb UTR ) in NIH 3T3 or 3T3 Ras cells. The 3 0 UTR did not significantly affect C/EBPb protein levels ( Figure 1A , bottom panel, lanes 4 and 6), indicating that 3 0 UTR elements do not confer C/EBPb silencing in this context. Interestingly, however, the proteins expressed from the two constructs exerted very different effects on cell proliferation. C/EBPb CR inhibited mitotic growth in a Rasdependent manner, as observed previously ( Figure 1A ; Supplementary Figure S1A ; Sebastian and Johnson, 2009) . By contrast, C/EBPb UTR displayed greatly reduced anti-proliferative activity relative to C/EBPb CR despite similar nuclear protein levels and mRNA expression ( Figure 1A ; Supplementary Figure S1B ). Cells expressing C/EBPb UTR also did not acquire the flattened morphology or expression of the senescence marker SA-bGal that were elicited by C/EBPb CR ( Figure 1B) . Moreover, C/EBPb CR potently inhibited the ability of 3T3 Ras cells to form transformed foci and grow as colonies in soft agar, whereas C/EBPb UTR was much less active in suppressing these transformed phenotypes (Supplementary Figure S1C) . To ensure that the UTR effect was not an artefact of expressing C/EBPb from a retroviral transcript, we generated stable 3T3
Ras transfectants carrying inducible C/EBPb CR or C/EBPb UTR plasmid vectors. A comparison of two clones expressing equivalent levels of C/EBPb CR and C/EBPb UTR confirmed that the 3 0 UTR efficiently blocks the anti-proliferative activity of C/EBPb (Supplementary Figure S1D) . Collectively, these observations suggested that the 3 0 UTR regulates C/EBPb function rather than its expression.
Electrophoretic mobility shift assay (EMSA) analysis of nuclear extracts from the NIH 3T3 cell lines demonstrated that C/EBPb CR DNA binding was enhanced by Ras V12 and homodimeric complexes were increased (Figure 1C and D; Lee et al, 2010b) . However, C/EBPb UTR DNA binding was unaffected by Ras and homodimer levels remained low. Ras also stimulated C/EBPb CR -driven transactivation of a reporter gene (2xC/EBP-luc) in transiently transfected NIH 3T3 cells, and this response was blunted by the 3 0 UTR (see Figure 3E ). The 3 0 UTR effect was not limited to NIH 3T3 cells, as Ras-induced DNA binding and transactivation by C/EBPb UTR was also reduced in transiently transfected human HEK293T (293T) cells ( Figure 1E ) and in HeLa cells (Supplementary Figure S2A) . Thus, the 3 0 UTR blocks posttranslational activation of C/EBPb in several immortalized/ transformed cell lines.
C/EBPb DNA binding is auto-inhibited by three elements in the N-terminal region of the protein, and mutation of these sequences increases basal DNA-binding activity (Lee et al, 2010a) . Appending the 3 0 UTR to this de-repressed triple mutant did not inhibit its constitutive DNA binding (Supplementary Figure S2B) , showing that the 3 0 UTR specifically blocks signal-induced activation of C/EBPb and not its binding activity in general. Furthermore, co-expressing a transcript containing the Cebpb 3 0 UTR alone in trans did not decrease C/EBPb CR DNA binding (Supplementary Figure S2C) . Hence, the 3 0 UTR acts in cis to suppress C/EBPb post-translational activation.
Since the related C/EBPa protein also has strong cytostatic activity (Johnson, 2005) , we investigated whether the Cebpa 3 0 UTR exerts similar inhibitory effects. Like C/EBPb CR , C/EBPa CR suppressed NIH 3T3 cell proliferation in a Rasdependent manner, and the Cebpa 3 0 UTR substantially blocked this anti-proliferative function without affecting C/EBPa expression (Supplementary Figure S3, upper panel) . Moreover, fusing the Cebpa 3 0 UTR to the Cebpb coding region (C/EBPb aUTR ) repressed C/EBPb's ability to inhibit cell proliferation (Supplementary Figure S3, lower panel) . Thus, the 3 0 UTRs of two Cebp genes contain transferable regulatory information that inhibits the Ras-induced cytostatic functions of both proteins.
An AU-rich element and its cognate binding protein, HuR, are required for 3 0 UTR inhibition To identify 3 0 UTR sequences that inhibit C/EBPb activity, we tested a set of 3 0 UTR deletion mutants in transfected 293T cells. This analysis showed that a region near the 3 0 -end of the UTR was required to suppress DNA binding and transactivation ( Figure 2A ). The inhibitory region spans a sequence previously shown to contain A/U-rich elements (AREs; Gantt et al, 2005; Cherry et al, 2008) , regulatory motifs found in many 3 0 UTRs that control mRNA decay and translation (Barreau et al, 2005) . The Cebpb 3 0 UTR contains a class III ARE composed of several G(U) 4À6 G repeats and lacks canonical AUUUA elements found in class I and II AREs (Xu et al, 1997) . To test its role in C/EBPb inhibition, we deleted the 110-nt Cebpb ARE region. This mutation (DARE) abolished the inhibitory effect of the 3 0 UTR ( Figure 2B ). Moreover, the ARE segment alone was nearly as effective as the complete 3 0 UTR in suppressing C/EBPb activity. Analysis of the mutant constructs in 3T3
Ras cells showed that DARE was unable to
Regulatory activity of 3 0 UTR elements in tumour cells SK Basu et al inhibit C/EBPb-induced growth arrest, whereas the ARE alone efficiently repressed C/EBPb ( Figure 2C ). EMSA confirmed that Ras-induced C/EBPb DNA binding was also inhibited by the ARE in these cells ( Figure 2D ). Hence, the ARE region is necessary and sufficient to suppress C/EBPb activation by oncogenic Ras. AREs are recognized by several sequence-specific RNAbinding proteins, including members of the Elav1/Hu protein (Barreau et al, 2005) . The ubiquitously expressed HuR protein binds to numerous mRNAs and controls their stability and translation (Abdelmohsen et al, 2008) . Because HuR was shown to associate with the Cebpb ARE (Gantt et al, 2005; Cherry et al, 2008) , we examined its role in 3 0 UTR inhibition. shRNA knockdown of HuR in 293T cells (HuR KD ) largely abolished 3 0 UTR inhibition of C/EBPb DNA binding and transactivation ( Figure 3A and C), and inhibition was restored by re-expression of HuR ( Figure 3B and C). HuR depletion did not affect activation of Ras effector kinases, as judged by induction of phosphorylated ERK, RSK, and Akt, nor was signalling disrupted by expression of the 3 0 UTR construct (Supplementary Figure S4) . Thus, the inhibitory effects of the 3 0 UTR are not due to impaired Ras signalling.
We also depleted HuR in NIH 3T3 cells to assess its role in 3 0 UTR-mediated inhibition of C/EBPb cytostatic activity. HuR silencing alone moderately decreased proliferation of control and Ras-transformed cells ( Figure 3D ). C/EBPb CR did not appreciably alter the growth of non-transformed 3T3-HuR Ras cells ( Figure 1B ). Hence, HuR is essential for the ability of the 3 0 UTR to suppress C/EBPb activation by Ras.
We further investigated whether HuR suppresses endogenous C/EBPb activity in human tumour cells, since this mechanism could be involved in establishing the transformed phenotype. HuR was ablated in A549 lung tumour cells and proliferation was assessed. HuR silencing decreased cell growth and colony formation (Supplementary Figure S6A) , consistent with studies showing that HuR depletion inhibits proliferation of RKO colorectal carcinoma cells (Wang et al, 2000) . To determine if this cytostatic response involves C/EBPb, we depleted C/EBPb in conjunction with HuR. C/EBPb knockdown in A549 cells overcame the effect of HuR ablation and increased proliferation and colony formation to levels exceeding even those of control cells. HuR silencing also led to a modest increase in endogenous C/EBPb DNA binding (Supplementary Figure S6B) . Similar results were obtained using MCF7 breast cancer cells and HeLa cells (Supplementary Figure S6C and D) . Thus, HuR ablation impairs proliferation of several immortalized human tumour cell lines in a manner that is partially dependent on Ras-induced post-translational modifications and homodimerization of C/EBP b are suppressed by the 3 0 UTR We next asked whether Ras-induced modifications on C/EBPb are regulated by the 3 0 UTR. Ser64 and Thr188 are phosphorylated by Cdk and ERK1/2 kinases, respectively, in response to oncogenic Ras (Nakajima et al, 1993; Shuman et al, 2004) . Analysis by western blotting using phosphospecific antibodies showed that both modifications were induced by Ras in C/EBPb CR , but were nearly undetectable in C/EBPb UTR ( Figure 4A ). By contrast, C/EBPb UTR underwent phosphorylation on Ser64 and Thr188 in HuR-depleted 293T cells ( Figure 4B ). Therefore, the 3 0 UTR blocks inducible phosphorylation on Ser64 and Thr188 in a HuR-dependent manner, consistent with C/EBPb UTR remaining in a lowactivity state.
Ras-induced activation of C/EBPb is associated with phosphorylation-mediated stabilization of homodimers that are resistant to displacement by C/EBPg (Lee et al, 2010b) . To determine whether the 3 0 UTR affects C/EBPb dimerization with C/EBPg, we expressed C/EBPb and Ras V12 in the presence of increasing amounts of C/EBPg. EMSA showed that C/EBPb CR heterodimerization with C/EBPg was relatively inefficient, whereas C/EBPb UTR readily formed heterodimers, especially at the highest dose of C/EBPg ( Figure 4C ). Similar results were seen in reporter assays, where increasing amounts of C/EBPg inhibited C/EBPb UTR transcriptional activity while that of C/EBPb CR was largely unaffected ( Figure 4D ). These findings indicate that the 3 0 UTR suppresses formation of transcriptionally active C/EBPb homodimers, which promote cell-cycle arrest and OIS, and allows preferential heterodimerization with C/EBPg. Table S1 ). Interestingly, 84 probes (70 genes) were induced by C/EBPb UTR but not by C/EBPb CR , showing that the 'lowactivity' C/EBPb UTR protein is able to stimulate gene transcription in a manner that is qualitatively distinct from the 'high activity' C/EBPb CR form. We also examined expression of individual senescenceassociated genes. Several inflammatory SASP genes (IL-6, GROa/Cxcl-1, Cxcl-2, Cxcl-5, and Ccr-1) ranked within the 400 transcripts showing highest fold induction by C/EBPb CR . Quantitative PCR demonstrated that these genes were induced to a much greater extent by C/EBPb CR than by C/EBPb UTR ( Figure 5C ). For example, Cxcl-1 mRNA was induced 253-fold by C/EBPb CR (relative to 3T3 Ras cells) and only 4.3-fold by C/EBPb UTR . Similarly, IL-1a, IL-1b, and S100a9 showed strong preferential activation by C/EBPb CR . In several cases, these transcripts were diminished in 3T3 Ras cells compared with control NIH 3T3 cells, possibly due to silencing of endogenous C/EBPb expression by oncogenic Ras (Sebastian and Johnson, 2009 ). Other C/EBPb CR -activated genes identified in the arrays that are known to regulate cell-cycle arrest, cell adhesion/migration, or tumour suppression include schlafen2, stefin A3, Btg2, p53 interacting protein 1, Vgll3, and thrombospondin 1 (Thbs1/TSP-1) ( We analysed the gene signatures induced by C/EBPb CR or C/EBPb UTR for associations with biological pathways or diseases using GeneGo MetaCore software. The 10 highest ranking associations for each category are shown in Figure 5D . C/EBPb CR -induced genes predominantly corresponded to pathways involved in inflammation and immune function (8/10 categories). By contrast, C/EBPb UTR targets were biased towards developmental pathways (4/10), cytoskeleton remodelling, and TGFb signalling (4/10). Of note, C/EBPb UTR -activated genes were strongly correlated with neoplastic diseases (7/10 categories), while C/EBPb CR scored highly for cardiovascular diseases, inflammation, and wounds/injuries but not for cancers. The fact that the C/EBPb UTR signature is correlated with TGFb signalling, epithelial-mesenchymal transition (EMT), and neoplastic diseases raises the intriguing possibility that this form of C/EBPb has pro-oncogenic/metastatic functions.
The 3
0 UTR excludes Cebpb mRNA from a perinuclear cytoplasmic domain that contains activated ERK1/2 kinase One possible mechanism for 3 0 UTR inhibition could involve localization of 3 0 UTR-containing transcripts to a cytoplasmic region where the newly translated protein cannot undergo Table S1 were analysed using GeneGo MetaCore software to identify associations with canonical biological pathways or disease states. Pattern matches were ranked by P-value (LOD score) and the top 10 categories are shown. activation. To address this possibility, we analysed the cytoplasmic location of Cebpb mRNAs using an mRNA tagging method in which transcripts are tethered to a nuclear-targeted GFP reporter (GFP-MS2-nls) via the RNA-binding domain of MS2 phage coat protein (Rook et al, 2000) . Multiple copies of the MS2 binding site were appended to the Cebpb CR and Cebpb UTR transcripts and the constructs were analysed in transfected NIH 3T3 cells by confocal microscopy. The GFP reporter alone was exclusively nuclear due to the presence of the nuclear localization signal ( Figure 6A ). Co-expression of Figure 6 The 3 0 UTR excludes Cebpb mRNA from a perinuclear region of the cytoplasm. Figure S9) . tagged Cebpb CR mRNA resulted in detectable cytoplasmic fluorescence, with the GFP signal distributed relatively uniformly throughout the cytoplasm. The Cebpb UTR transcript also promoted cytoplasmic localization of the GFP reporter, but in this case GFP was excluded from a region surrounding the nucleus, with fluorescence concentrated in more peripheral areas. Although such perinuclear exclusion was not observed for every GFP-positive cell (79.5 ± 2.4%), the pattern was clearly distinct from that of Cebpb CR mRNA, which was nearly always uniformly distributed (93.3±1.8%). Similar results were obtained using HeLa cells (Supplementary Figure S8) . Hence, the 3 0 UTR restricts Cebpb mRNA to a peripheral cytoplasmic domain.
Deleting the ARE led to uniform distribution of the Cebpb UTR transcript ( Figure 6B ). Moreover, Cebpb ARE mRNA was peripherally localized in a pattern similar to Cebpb UTR . Compartmentalization of the Cebpb UTR transcript required HuR, as it displayed more uniform distribution in HuR KD NIH 3T3 cells compared with its peripheral restriction in control cells ( Figure 6C ; Supplementary Figure S9) . Thus, the presence of Cebpb mRNA in the perinuclear region is strictly correlated with C/EBPb activation and induction of cell-cycle arrest, while exclusion from this domain is associated with diminished protein activity. To further test the mRNA localization model, we replaced the 3 0 UTR with three copies of the b-actin 3 0 UTR 'zipcode' element, a sequence that directs b-actin transcripts to the peripheral cytoplasm and leading lamellae of migrating cells (Kislauskis et al, 1994) . The Cebpb 3 Â ZIP transcript was predominantly localized to the periphery in NIH 3T3 cells, substantially mimicking the pattern observed for the Cebpb 3 0 UTR (Supplementary Figure S10) . Significantly, the zipcode sequence also suppressed activation of C/EBPb DNA binding and transactivation in NIH 3T3 cells and 293T cells (Supplementary Figure S11) , although its inhibitory effect was somewhat less than that of the 3 0 UTR. This quantitative difference may result from less efficient exclusion of the zipcode-containing transcript from the perinuclear region. Nevertheless, our results corroborate the notion that exclusion of Cebpb mRNA from the perinuclear compartment blunts C/EBPb post-translational activation by Ras signalling.
These data suggest that C/EBPb UTR protein synthesis in the cytoplasmic periphery could restrict its access to critical modifying enzyme(s). C/EBPb activation by Ras is highly dependent on Raf-MEK-ERK signalling, inducing direct phosphorylation on Thr188 by ERK1/2 and other modifications (Nakajima et al, 1993; Mo et al, 2004; Lee et al, 2010b) . Since Thr188 phosphorylation was blocked by the 3 0 UTR (Figure 4A ), we examined the subcellular location of activated ERK1/2 in NIH 3T3 cells expressing a 4-OHT-inducible H-Ras V12 protein, ER:Ras V12 (Dajee et al, 2002) . Western blotting showed significantly increased levels of phospho-ERK 24 and 48 h after induction ( Figure 7A ). Immunofluorescent staining of the induced cells revealed a strong p-ERK signal that occurs in a punctate pattern confined mainly to the perinuclear region (Supplementary Figure S12) . Nuclear p-ERK levels were low or undetectable in these cells, showing that activated ERK is predominantly perinuclear in cells undergoing sustained Ras signalling. Similar perinuclear p-ERK localization was observed in Ras V12 -expressing (senescent) normal human fibroblasts (Gaumont -Leclerc et al, 2004) . Notably, simultaneous imaging of p-ERK and Cebpb mRNA (GFP) revealed a striking overlap between p-ERK and the perinuclear region that is devoid of Cebpb UTR mRNA ( Figure 7B ). These findings provide compelling evidence that C/EBPb protein synthesis in the perinuclear compartment facilitates coupling with p-ERK (and possibly other C/EBPb-activating kinases), while 3 0 UTRmediated exclusion of the Cebpb transcript prevents functional interactions between nascent C/EBPb and Ras effector kinase(s).
3
0 UTR inhibition is absent in primary fibroblasts C/EBPb is required for OIS in primary MEFs (Sebastian et al, 2005) , and endogenous C/EBPb DNA-binding activity is stimulated by Ras V12 in these cells ( Figure 8A ; Lee et al, 2010b) . These observations suggested that 3 0 UTR inhibition might be lacking in primary fibroblasts. Consistent with this prediction, both C/EBPb CR and C/EBPb UTR efficiently inhibited proliferation of Ras-expressing Cebpb À/À MEFs and showed comparable transactivation of a reporter gene ( Figure 8B and C). IMR90 human diploid fibroblasts also undergo C/EBPb-dependent senescence in response to oncogenic stress (Kuilman et al, 2008) . Accordingly, C/EBPb CR and C/EBPb UTR displayed similar Ras-stimulated DNA-binding and transcriptional activity in these cells (Supplementary Figure S13A and B). Moreover, both transcripts showed uniform cytoplasmic distribution in MEFs and IMR90 cells ( Figure 8D; Supplementary Figure S13C ). Hence, 3 0 UTR inhibition is reduced or absent in primary fibroblasts and correlates with an absence of Cebpb mRNA compartmentalization, allowing C/EBPb to become activated and induce proliferative arrest in primary cells expressing oncogenic Ras.
We next asked whether cell-specific control of 3 0 UTR inhibition involves HuR. As HuR is predominantly nuclear but undergoes nucleocytoplasmic shuttling in a regulated manner (Doller et al, 2008) , we investigated whether differential 3 0 UTR inhibition in MEFs and NIH 3T3 fibroblasts is associated with changes in HuR levels or subcellular partitioning. Cytoplasmic HuR levels were comparable in both control cell populations (Supplementary Figure S14, left  panel, lanes 1 and 3) . However, oncogenic Ras decreased the cytoplasmic HuR pool in MEFs, whereas it increased cytosolic HuR in NIH 3T3 cells (Supplementary Figure S14 , left panel, lanes 2 and 4). Nuclear HuR levels were correspondingly increased or decreased, respectively (Supplementary Figure S14, right panel) . Thus, elevated cytoplasmic HuR is observed in immortalized cells under conditions of oncogenic stress. This suggests that increased cytosolic HuR in transformed 3T3
Ras cells engages the C/EBPb 3 0 UTR repression mechanism. By contrast, primary cells undergoing OIS display reduced levels of cytoplasmic HuR and, concomitantly, lack C/EBPb 3 0 UTR inhibition.
Discussion
3 0 UTRs have well-established roles in controlling mRNA degradation and translation, often through the actions of miRNAs (Conne et al, 2000; Moore, 2005; Bartel, 2009 ). Here, we report a previously unrecognized function for 3 0 UTRs in regulating signal-induced activation of the protein product, a process that we term '3 0 UTR regulation of protein activity' or UPA ( Figure 9A) . UPA inhibits the cytostatic activities of both C/EBPb and C/EBPa in Ras V12 -expressing cells, showing that this mechanism regulates at least two members of the C/EBP family. At present, it is unclear how many other proteins are subject to UPA control. However, since an estimated 5-8% of human genes contain ARE-like sequences (Bakheet et al, 2003) , similar mechanisms could theoretically regulate the activities of many proteins.
C/EBPb activity is constrained by auto-inhibition and heterodimerization with C/EBPg, and these inhibitory effects are reversed by oncogenic Ras signalling via the MEK/ERK/ RSK kinase cascade (Lee et al, 2010a, b) . Our results show that UPA quells de-repression of C/EBPb by oncogenic Ras, providing another barrier to C/EBPb activation that prevents unscheduled cell-cycle arrest. UPA is restricted to immortalized and transformed cells, raising the possibility that genetic events rendering cells susceptible to transformation by Ras (i.e., loss of tumour suppressors) are involved in activating the C/EBPb UPA system. This mechanism could link inhibition of C/EBPb cytostatic activity with oncogenic transformation and may be essential for senescence bypass in tumour cells. Because C/EBPb also has pro-oncogenic functions and can promote cell proliferation and survival (Sebastian and Johnson, 2006) , we suggest that UPA does not inhibit all C/EBPb activities. Indeed, the C/EBPb UTR -induced gene signature was highly correlated with cancers whereas that of C/EBPb CR tended to be associated with inflammation and non-neoplastic diseases ( Figure 5D ). Thus, activation of genes associated with cancer, EMT, and TGFb signalling may underlie the known pro-tumourigenic effects of endogenous C/EBPb, which is expressed from a 3 0 UTR-containing transcript.
The Cebpb ARE region is necessary and sufficient for UPA, which also requires the ARE-binding protein, HuR. HuR positively regulates cell proliferation, in part through binding to the 3 0 UTRs of cyclins A and B and stabilizing the mRNAs encoding these key cell-cycle regulators (Wang et al, 2000) . C/EBPb depletion in several human tumour cell lines partially or completely abrogated the cytostatic response to HuR ablation (Supplementary Figure S6) . Thus, C/EBPb is another important HuR target, and HuR may stimulate cell proliferation at least in part through the UPA mechanism. The connection between HuR and C/EBPb was also observed in NIH 3T3 cells, where HuR depletion converted C/EBPb UTR into a growth suppressor ( Figure 3D ). These experiments show that HuR inhibits the cytostatic activity of C/EBPb, an idea that is . Cells were starved for serum and lysates analysed for p-ERK and total ERK by immunoblotting following 4-OHT stimulation. p-ERK levels in non-transduced, serum-starved NIH 3T3 cells are shown for comparison. (B) Phospho-ERK1/2 is located in the perinuclear region that lacks Cebpb UTR mRNA. 3T3 ER:RasV12 cells were co-transfected with the GFP-MS2-nls reporter and tagged Cebpb vectors, induced with 4-OHT for 48 h, immunostained for p-ERK (Texas Red), and both markers visualized by confocal fluorescence microscopy.
Regulatory activity of 3 0 UTR elements in tumour cells SK Basu et al further supported by the fact that cytoplasmic HuR levels are decreased in senescent fibroblasts (Wang et al, 2001 ; Supplementary Figure S14) , possibly due to increased energetic stress and elevated AMP-dependent signalling (Wang et al, 2003) . The diminished cytoplasmic HuR pool in primary cells may alleviate negative regulation by the 3 0 UTR and permit C/EBPb activation.
The UPA mechanism proposed here also relates to the reported association between HuR and cancer. Since elevated HuR levels and/or cytoplasmic abundance have been linked to increased incidence or malignancy of various cancers Ido et al, 2008; MazanMamczarz et al, 2008; Yoo et al, 2009) , we propose that implementation of C/EBPb UPA contributes to the progression of premalignant tumours (with senescent features) to fully malignant cancers. Although C/EBPb UTR is resistant to activation in immortalized/transformed cells, the protein is nonetheless expressed and transported to the nucleus. Thus, UPA provides a plausible mechanism for generating the low activity, mostly heterodimeric form of C/EBPb that may have pro-oncogenic functions in advanced cancers.
Although the full details of UPA remain to be established, our studies strongly implicate the subcytoplasmic location of C/EBPb synthesis as a critical factor in its post-translational activation by Ras signalling ( Figure 9B) . In tumour cells, the 3 0 UTR excludes Cebpb transcripts from a perinuclear domain through a HuR-dependent mechanism. HuR itself does not exhibit the same cytoplasmic distribution and tends to be localized throughout the cytosol in punctate structures (Zou et al, 2006) , suggesting that HuR is only one component of a larger complex that assembles on the ARE region to regulate Cebpb mRNA localization. Importantly, the perinuclear region corresponds precisely to the site of active ERK1/2 in cells expressing oncogenic Ras. p-ERK and newly synthesized C/EBPb are apparently capable of interacting in this compartment, allowing C/EBPb to undergo activation before nuclear translocation. Since C/EBPb de-repression involves additional modifications besides ERK1/2 phosphorylation on Thr188, it is likely that other kinases are also enriched in the perinuclear space. This possibility warrants further investigation. In further support of our model, Cebpb mRNA partitioning was not observed in UPA has similarities to, but is distinct from, the 3 0 UTR zipcode mechanism that localizes b-actin mRNA to the leading edge of migrating fibroblasts (Kislauskis et al, 1994) . Zipcodedirected mRNA trafficking restricts b-actin translation to a subcellular domain where high levels of actin are required. In contrast, UPA does not alter the ultimate destination of C/EBPb (the nucleus) but rather controls its post-translational activation. A study of mRNA localization in Drosophila embryos showed that 71% of the transcripts analysed were distributed in distinct spatial patterns (Lecuyer et al, 2007) . Thus, differential mRNA localization may be a common means of controlling protein function and activity. The extent to which 3 0 UTRs specify this spatial patterning is unknown, but they are likely to have a significant role.
In light of similarities between cancer cells and stem/ progenitor cells (Reya et al, 2001) , an important physiologic function of UPA may involve constraining the anti-proliferative activity of C/EBP proteins in progenitor or transit amplifying cells during development. C/EBPa is expressed in proliferating haematopoietic progenitors but is also required for subsequent terminal differentiation of granulocytes and functions as a tumour suppressor in myeloid leukaemias (Nerlov, 2004) . Therefore, UPA could regulate haematopoiesis and other developmental processes by restricting the anti-proliferative effects of C/EBPa and C/EBPb to the appropriate lineages and stage of differentiation. Future studies should reveal whether this is an important biological role for C/EBP UPA. In addition, further elucidation of the proteins and pathways responsible for establishing UPA in tumour cells may reveal novel targets for cancer therapy, since disrupting UPA would be predicted to suppress tumour growth and induce senescence.
Materials and methods
Cell lines and reagents NIH 3T3 cells were obtained from ATCC and cultured in DMEM medium with 10% calf serum. HEK293T cells, WT and Cebpb À/À MEFs (Sebastian et al, 2005) , A549 cells, MCF7 cells, HeLa cells, and IMR90 cells were cultured in DMEM with 10% fetal bovine serum. Phoenix ecotropic and amphotropic packaging cells were grown in the same medium. C/EBPb (C-19), b-actin (C11), HuR (3A2), and ERK1/2 (K23) antibodies were obtained from Santa Cruz Biotechnology. Phospho-C/EBPb (T188) antibody was obtained from Abcam (pT235) and phospho-S64 antibody has been described previously (Shuman et al, 2004) . Phospho-p90 RSK (S380), Akt, phospho-ERK1/2 (T202/Y204), and pAkt (S473) antibodies were obtained from Cell Signaling Technology. RSK2 and RSK3 antisera were kindly provided by M Ernst and N Rice.
Plasmids and retroviral constructs
Details of the various expression vectors are presented in the Supplementary data.
Stable transfection and retroviral transduction
Retroviral infection was performed as described (Sebastian et al, 2005) . After drug selection, cells were used for proliferation, colony formation, and focus formation assays. Knockdown of C/EBPb and HuR expression was achieved using pSuperRetro vector-mediated RNAi technology (Oligoengine). The siRNA sequences for C/EBPb (GATGTTCCTGCGGGGTTGT; Sebastian and Johnson, 2009 ) and HuR (GAGGCAATTACCAGTTTCA; Lal et al, 2004) were inserted into pSuperRetro; retroviral supernatants were produced using Phoenix packaging cells. Permanent clones of HuR KD HEK293T, A549, and MCF7 cells were selected, and individual colonies were expanded for further analysis. For inducible expression of C/EBPb, NIH 3T3 cells were transfected with pMTCB6-C/EBPb ( ± 3 0 UTR) using CaPO 4 precipitation, transfectants were selected with antibiotics, and individual clones were isolated for proliferation assays. C/EBPb expression was induced with 50 mM ZnSO 4 .
Proliferation, transformation, and senescence assays Cell proliferation and transformation were assayed using standard methods (see Supplementary data). For SA-bGal staining, cells were plated in 12-well dishes (12 Â10 3 cells/well) and stained using a senescence detection kit (EMD Biosciences, USA) according to the manufacturer's instructions. Positive cells were quantified by scoring 100 cells each from two different wells. Protein analysis and EMSA Nuclear and cytoplasmic extracts were prepared from the retrovirally infected or transiently transfected cells, as described (Sebastian and Johnson, 2009) . EMSA was performed by incubating nuclear extracts (normalized for C/EBPb levels) with 32 P-labelled oligonucleotide probe corresponding to a consensus C/EBP binding site, as described (Lee et al, 2010b) . In these experiments, b-actin controls were not included because the extracts were equalized for C/EBPb levels. For supershift assays, extracts were pre-incubated with 200 ng antibodies against C/EBPb or C/EBPg (Parkin et al, 2002) for 30 min before the binding reaction. DNA-protein complexes were resolved on 6% polyacrylamide/1 Â TBE gels.
Transient transfection and luciferase assays
mRNA localization
The GFP-MS2-nls reporter system has been described previously (Rook et al, 2000) . The pcDNA-Cebpb-Ms2b vector was constructed by cloning the multiple MS2 binding sites from the RSV-lacZ-MS2b vector (Rook et al, 2000) downstream of the Cebpb coding region, without or with the 3 0 UTR, using BamHI/BglII sites. The Cebpb CR -Ms2b vector was modified to Cebpb 3 Â ZIP -Ms2b by cloning three copies of the 54-nt b-actin zipcode element (5 0 -ACCGGACTGT-TACCAACACCCACACCCCTGTGATGAAACAAAACCCATAAATGC-3 0 ) (Kislauskis et al, 1994) downstream of the MS2 binding sites using BamHI/HindIII restriction sites. NIH 3T3 cells, HeLa cells, IMR90 cells, and WT MEFs were plated at 5 Â10 4 cells/35 mm dish and transfection was carried out using Polyfect (Qiagen) (for NIH 3T3), Fugene 6 (Roche) (for HeLa), and Transpass D2 and Transpass V (New England Biolabs) (for IMR90 and MEFs, respectively). After 36 h, the cells were fixed with 3.6% formaldehyde for 10 min and stained with 1 mg/ml DAPI (Sigma). Fluorescence images were taken with a Zeiss confocal microscope.
Immunofluorescence
Immunostaining was performed as described (Sebastian et al, 2005) with minor modifications. Cells (5 Â10 4 /35 mm dish) were fixed with 4% paraformaldehyde for 10 min and incubated with phospho-ERK1/2 primary antibody followed by goat anti-rabbit IgG secondary antibody conjugated with Texas red (Santa Cruz Biotechnology sc-2780). Fluorescence images were taken with a Zeiss confocal microscope.
Microarray gene expression profiling
Genome-wide expression analysis was carried out using RNA isolated from the indicated NIH 3T3 cell populations (RNeasy, Qiagen) . Each cell population was generated by retroviral transduction, in triplicate, and RNAs from each replicate were used for independent microarray hybridization analysis (LMT/Affymetrix Group, SAIC-Frederick). Labelled cDNAs were hybridized to GeneChip Mouse Genome 430 2.0 arrays (Affymetrix). The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al, 2002) and are accessible through GEO Series accession number GSE30834 (http://www.ncbi.nlm. nih.gov/geo/query/acc.cgi?acc=GSEohttp://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE308344 30834ohttp://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=GSE308344). Detailed statistical methods are described in Supplementary data. qPCR RNA isolated from NIH 3T3 cell populations was used to determine expression levels of individual genes. cDNA was generated (Reverse Transcription Kit, Qiagen) from total RNA and qPCR was performed using SYBR Green with QuantiTect Primers (Qiagen) and normalized against b-actin or b2-microglobulin. Analysis was performed using an Applied Biosystems 7500 Real Time PCR System and SDS Software (version 1.4). For each gene, a random representative of the triplicate RNA samples used for microarray analysis was selected for qPCR. Relative gene expression values were determined twice (in triplicate) and the data were averaged. Error bars represent standard error of mean expression levels. For primer sequences, see Supplementary data.
Gene function and pathway analysis
The association of gene expression signatures with biological pathways and diseases was performed using MetaCore software (MetaCore TM , GeneGo, St Joseph, MI). Gene symbols of transcripts specifically upregulated by C/EBPb CR (312 genes) or C/EBPb UTR (70 genes) (i.e., the non-overlapping sets in Supplementary Table S1) were uploaded to GeneGo and the data were compared with the gene signatures for canonical biological pathways or specific diseases. Associations were ranked by P-value (LOD score; logarithm of the odds) and the top 10 matches were selected.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
